

University of Dundee

## Vitamin K supplementation to improve vascular stiffness in CKD

Witham, Miles; Lees, Jennifer S.; White, Myra; Band, Margaret; Bell, Samira; Chantler, Donna J.

*Published in:*  
Journal of the American Society of Nephrology

*DOI:*  
[10.1681/ASN.2020020225](https://doi.org/10.1681/ASN.2020020225)

*Publication date:*  
2020

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

### *Citation for published version (APA):*

Witham, M., Lees, J. S., White, M., Band, M., Bell, S., Chantler, D. J., Ford, I., Fulton, R., Kennedy, G., Littleford, R., McCrea, I. V., McGlynn, D., Panarelli, M., Ralston, M. R., Rutherford, E., Severn, A., Thomson, N., Traynor, J. P., Struthers, A. D., ... Mark, P. B. (2020). Vitamin K supplementation to improve vascular stiffness in CKD: The K4Kidneys randomized controlled trial. *Journal of the American Society of Nephrology*, 31(10), 2434-2445. <https://doi.org/10.1681/ASN.2020020225>

### **General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

## **Supplemental Material**

### **Contents**

- 1. Details of assays used in the K4Kidneys trial**
- 2. Details of studies included in the meta-analysis**
  - 3. Time to first fall**
  - 4. Vascular calcification results**
- 5. Forest plots for vascular calcification**

### 1. Supplementary Table: Details of assays used in the trial

Assay	Manufacturer	Coefficient of variation	
		Intra-assay	Inter-assay
Fetuin A	R+D Systems Quantikine ELISA	3.5-4.2%	8.5-8.8%
Fibroblast Growth Factor 23	Immutopics C-terminal ELISA	3.3-11.5%	3.3-11.5%
Osteocalcin	R+D Systems Quantikine ELISA	5.2-5.4%	7.3-13.8%
Insulin	Alpco ELISA	4.8-6.9%	4.9-13.5%
25-hydroxyvitamin D	Diasorin LIAISON	2.9-8.4%	5.6-10.1%
1,25 dihydroxyvitamin D	Diasorin LIAISON XL	5.3-8.4%	8.2-8.8%
dp-ucMGP	IDS-iSYS InaKtif MGP	≤ 5.0% (between 910 and 7312 pmol/L)	≤ 7.3% between 939 and 7386 pmol/L)
Tartrate-resistant acid phosphatase-5b	Cusabio ELISA	6.9%	6.3-14.3%
N-terminal pro B-type natriuretic peptide	Meso Scale Discovery ELISA	8.0%	13.2-15.5%


dp-ucMGP: desphospho-uncarboxylated matrix Gla protein

\*A threshold of 900 pmol/L was used as the lowest reportable concentration of dp-ucMGP. Assay performance below this concentration was found to be non-linear on dilution testing, thus values below 900 pmol/L cannot be reported with accuracy.

## 2. Supplementary Table: Details of studies included in the meta-analysis

Author	Year	Country	Baseline N	Population	Intervention	Dose (mcg/day)	Comparator	Duration (months)	Outcome measure
Braam <sup>33</sup>	2004	Netherlands	121	Healthy	K1 +Multivitamin (incl vitamin D)	1000	Multivitamin (incl vitamin D)	36	Compliance coefficient (mm <sup>2</sup> /kPa)
Shea <sup>34</sup>	2009	USA	295	Older adults	K1 +Multivitamin (incl vitamin D)	500	Multivitamin (incl vitamin D)	36	Coronary artery calcification score
Knapen <sup>35</sup>	2015	Netherlands	244	Postmenopausal women	K2-MK7	180	Placebo	36	Pulse wave velocity (SphygmoCor)
Kurnatowska <sup>16</sup>	2015	Poland	40	CKD	K2-MK7 + Vitamin D	90	Vitamin D	9	Coronary artery calcification score
Fulton <sup>18</sup>	2016	Scotland	80	Older adults, vascular disease	K2-MK7	100	Placebo	6	Pulse wave velocity (SphygmoCor)
Brandenburg <sup>36</sup>	2017	Germany	72	Aortic stenosis or sclerosis	K1	2000	Placebo	12	Aortic valve calcification score
Oikonomaki <sup>37</sup>	2019	Greece	102	Patients undergoing haemodialysis	K2-MK7	200	Usual care	12	Abdominal aortic calcification score
Zwakenberg <sup>39</sup>	2019	Netherlands	68	Patients with type 2 diabetes mellitus	K2-MK7	360	Placebo	6	Femoral artery calcification score
De Vriese <sup>38</sup>	2020	Belgium	88	Patients undergoing haemodialysis with atrial fibrillation	K2-MK7 + Rivaroxaban	857	Rivaroxaban	18	Coronary artery calcification score

### 3. Supplementary Figure. Time to first fall




Time to first fall: HR 0.79 (95% CI 0.37 to 1.69, p=0.54)

#### 4. Vascular calcification results

	Vitamin K Mean (SD)	Placebo Mean (SD)	Treatment effect* (95% CI)	p
Mean Aortic calcification score (SD) at 12 months	4.8 (5.1)	4.2 (5.3)	-0.3 (-0.8 to 0.2)	0.31
[Median (Q1,Q3)]	[3 (0,8)]	[3 (0,5)]		
Mean Aortic calcification score (SD) at 12 months (excluding zero scores)	7.0 (4.8)	6.5 (5.3)	-0.3 (-1.1. to 0.42)	0.37
Change in aortic calcification score between baseline and 12 months (SD)	0.0 (1.4)	0.3 (1.4)	-0.3 (-0.8 to 0.2)	0.31
No detectable calcification at baseline (%)	18 (30.0)	22 (36.7)	Odds ratio 0.2 (0.0 to 4.3)	0.30
No detectable calcification at 12 months (%)	19 (31.7)	21 (35.6)		

## 5. Forest plots – vascular calcification

### a) Excluding current trial



b) Including current trial

